CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2017—Qiagen launched the QIAseq cfDNA All-in-One kit, combining cell-free DNA extraction and library preparation in a dedicated solution for liquid biopsy analysis on next-generation sequencing platforms. The kit integrates with Qiagen’s PAXgene Blood ccfDNA tube as well as with the company’s bioinformatics workflow for cfDNA, creating a streamlined testing solution that aims to allow faster, more convenient, and reliable analysis of cell-free DNA from sample collection to interpreted result.
Qiagen also unveiled an enhanced bioinformatics workflow for hereditary and rare diseases, offering unique capabilities for research using liquid biopsies in noninvasive prenatal testing as well as cancer biomarker discovery. The company rolled out the solutions at the American Society of Human Genetics 2016 annual meeting in Vancouver.
The company’s enhanced hereditary disease solution provides a streamlined, easy-to-use analysis and interpretation workflow for NGS data from liquid biopsies. The bioinformatics solution enables labs to achieve more accurate detection and the highest sensitivity in identifying variants. Integrating Qiagen’s biomedical genomics workbench, ingenuity variant analysis, and other components, the solution aims to address NGS bottlenecks and ensure that no pathogenic variant is missed.
Qiagen, 240-686-7700